Skip to content
2000
image of Sexual Dysfunctions in Chronic Liver Diseases: A Narrative Review on Prevalence and Putative Pathophysiologic Mechanisms

Abstract

Introduction/Objectives

Chronic liver diseases have been reported to be associated with altered sexual function. The existing gap in understanding the pathophysiological mechanisms linking sexual disorders and chronic liver diseases may explain the lack of attention given to sexual health in this cohort of patients. We, therefore, aimed at reviewing the available evidence linking chronic liver diseases and sexual dysfunction in both sexes.

Methods

A search of the PubMed database was conducted for the period between January 1995 and July 2024 using the following terms: “chronic liver disease”, “liver cirrhosis”, “viral hepatitis B”, “viral hepatitis C”, “non-alcoholic fatty liver disease”, “metabolic dysfunction associated steatotic liver disease” “alcoholic liver disease” and “erectile dysfunction,” “hypogonadism”, “infertility”.

Results

A total of 96 articles were reviewed, including preclinical original research articles, human observational and clinical studies, systematic reviews, and meta-analyses. We found that sexual dysfunctions are often associated with chronic liver diseases and that this depends on the degree of the underlying liver damage and etiology. Contributing factors may include hormonal imbalances, psychological disturbances, and endothelial dysfunction.

Discussion

The degree of liver function impairment, the specific etiology, particularly metabolic dysfunction associated steatotic liver disease, and drugs used in the management of chronic liver diseases all contribute to sexual dysfunction in this clinical setting.

Conclusions

Chronic liver diseases are associated with a wide range of sexual dysfunctions in both sexes, causing an altered quality of life. This suggests that sexual function should be assessed in this clinical setting in order to reach a prompt diagnosis and start appropriate treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871355207250411202640
2025-04-24
2025-09-15

  • From This Site

    /content/journals/rrct/10.2174/0115748871355207250411202640
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McCabe M.P. Sharlip I.D. Lewis R. Incidence and prevalence of sexual dysfunction in and risk factors of sexual dysfunction in men and women. A consensus statement from the fourth international consultation on sexual medicine 2015. J. Sex. Med. 2016 13 2 144 10.1016/j.jsxm.2015.12.034
    [Google Scholar]
  2. Laumann E.O. Nicolosi A. Glasser D.B. Sexual problems among women and men aged 40–80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int. J. Impot. Res. 2005 17 1 39 57 10.1038/sj.ijir.3901250 15215881
    [Google Scholar]
  3. Jannini E.A.S.M. = SM: The interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner. Sex. Med. Rev. 2017 5 3 349 364 10.1016/j.sxmr.2017.04.002 28596070
    [Google Scholar]
  4. Chrysavgis L. Adamantou M. Angelousi A. Cholongitas E. The association of testosterone with sarcopenia and frailty in chronic liver disease. Eur. J. Clin. Invest. 2024 54 2 e14108 10.1111/eci.14108 37837304
    [Google Scholar]
  5. Duman D.G. Biçakci E. Çelikel Ç.A. Akbal C. Nonalcoholic fatty liver disease is associated with erectile dysfunction: A prospective pilot study. J. Sex. Med. 2016 13 3 383 388 10.1016/j.jsxm.2015.12.030 26853046
    [Google Scholar]
  6. Zsoldos M. Pajor A. Pusztafalvi H. Relation between sexual dysfunction and metabolic syndrome. Orv. Hetil. 2019 160 3 98 103 10.1556/650.2019.31235 30640528
    [Google Scholar]
  7. Hasanain A.F.A. Mahdy R.E. Mahran A.M.A.R. Safwat A.S.M. Mohamed A.O. Abdel-Aal S.M. Erectile dysfunction in patients with nonalcoholic fatty liver disease. Arab J. Gastroenterol. 2017 18 1 21 24 10.1016/j.ajg.2017.02.002 28325476
    [Google Scholar]
  8. Vignozzi L. Filippi S. Comeglio P. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Mol. Cell. Endocrinol. 2014 384 1-2 143 154 10.1016/j.mce.2014.01.014 24486698
    [Google Scholar]
  9. Qu X. Donnelly R. Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome. Int. J. Mol. Sci. 2020 21 21 8191 10.3390/ijms21218191 33139661
    [Google Scholar]
  10. Sinclair M. Grossmann M. Gow P.J. Angus P.W. Testosterone in men with advanced liver disease: Abnormalities and implications. J. Gastroenterol. Hepatol. 2015 30 2 244 251 10.1111/jgh.12695 25087838
    [Google Scholar]
  11. Zang G. Sun X. Sun Y. Chronic liver diseases and erectile dysfunction. Front. Public Health 2023 10 1092353 10.3389/fpubh.2022.1092353 36684968
    [Google Scholar]
  12. Romano L. Granata L. Fusco F. Sexual dysfunction in patients with chronic gastrointestinal and liver diseases: A neglected Issue. Sex. Med. Rev. 2022 10 4 620 631 10.1016/j.sxmr.2021.02.002
    [Google Scholar]
  13. Younossi Z. Anstee Q.M. Marietti M. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018 15 1 11 20 10.1038/nrgastro.2017.109 28930295
    [Google Scholar]
  14. Federico A. Dallio M. Masarone M. Persico M. Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction. Eur. Rev. Med. Pharmacol. Sci. 2016 20 22 4731 4741 27906428
    [Google Scholar]
  15. Rosato V. Masarone M. Dallio M. Federico A. Aglitti A. Persico M. NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome. Int. J. Environ. Res. Public Health 2019 16 18 3415 10.3390/ijerph16183415 31540048
    [Google Scholar]
  16. Eslam M. Sanyal A.J. George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 1999 158 7 1999 10.1053/j.gastro.2019.11.312
    [Google Scholar]
  17. Targher G Byrne CD Tilg H MASLD: A systemic metabolic disorder with cardiovascular and malignant complications. 2024
    [Google Scholar]
  18. Rinella M.E. Lazarus J.V. Ratziu V. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. 2024 29 1 101133 10.1016/j.aohep.2023.101133 37364816
    [Google Scholar]
  19. Kaya E. Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): A multi-systemic disease beyond the liver. J. Clin. Transl. Hepatol. 2022 10 2 329 338 10.14218/JCTH.2021.00178 35528971
    [Google Scholar]
  20. Tarik Kani H. Emre Sener T. Emre Aykut U. Ozer Demirtas C. Keklikkiran C. Causes of erectile dysfunction in non-alcoholic fatty liver disease. Hepatol. Forum 2021 2 2 60 63 10.14744/hf.2021.2021.0012
    [Google Scholar]
  21. Song M.J. Choi J.Y. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin. Front. Endocrinol. (Lausanne) 2022 13 1053709 10.3389/fendo.2022.1053709 36482993
    [Google Scholar]
  22. Sakr H.F. Hussein A.M. Eid E.A. AlKhateeb M. Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: A protective role for testosterone. Steroids 2018 135 21 30 10.1016/j.steroids.2018.04.004 29674209
    [Google Scholar]
  23. Yilmaz M. Odabas O. Karaaslan M. Predicting risk of erectile dysfunction in patients with nonalcoholic fatty liver disease. Andrologia 2021 53 7 e14091 10.1111/and.14091 33951744
    [Google Scholar]
  24. Li Y. Liu L. Wang B. Chen D. Wang J. Nonalcoholic fatty liver disease and alteration in semen quality and reproductive hormones. Eur. J. Gastroenterol. Hepatol. 2015 27 9 1069 1073 10.1097/MEG.0000000000000408 26062079
    [Google Scholar]
  25. Hawksworth D.J. Burnett A.L. Nonalcoholic fatty liver disease, male sexual dysfunction, and infertility: Common links, common problems. Sex. Med. Rev. 2020 8 2 274 285 10.1016/j.sxmr.2019.01.002 30898592
    [Google Scholar]
  26. Montorsi P. Ravagnani P.M. Galli S. Ali S.G. Briganti A. The triad of endothelial dysfunction, cardiovascular disease, and erectile dysfunction: Clinical implications. Eur. Urol. 2009 8 2 58 66 10.1016/j.eursup.2008.10.010
    [Google Scholar]
  27. Tilg H. Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000 343 20 1467 1476 10.1056/NEJM200011163432007 11078773
    [Google Scholar]
  28. Carneiro F.S. Sturgis L.C. Giachini F.R.C. TNF-α knockout mice have increased corpora cavernosa relaxation. J. Sex. Med. 2009 6 1 115 125 10.1111/j.1743‑6109.2008.01029.x 19170842
    [Google Scholar]
  29. Eren H. Horsanali M.O. The independent association of non-alcoholic fatty liver disease with lower urinary tract symptoms/benign prostatic hyperplasia and erectile function scores. BJU Int. 2019 124 2 329 10.1111/bju.14753
    [Google Scholar]
  30. Haider A. Gooren L.J.G. Padungtod P. Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp. Clin. Endocrinol. Diabetes 2010 118 3 167 171 10.1055/s‑0029‑1202774 19472103
    [Google Scholar]
  31. Taylor F.L. Levine L.A. Peyronie’s disease. Urol. Clin. North Am. 2007 34 4 517 534
    [Google Scholar]
  32. Crocetto F. Barone B. Manfredi C. Trama F. Romano L. Are insulin resistance and NAFLD associated with peyronie’s disease? A pilot study. Physiol Pharmacol 2022 73 15 24 10.26402/jpp.2022.1.05 35639037
    [Google Scholar]
  33. Glina F.P.A. Lopes L. Silva R.S. Barros E.A.C. Biselli B. Glina S. Do statins decrease testosterone in men? Systematic review and meta-analysis. Int. Braz J Urol 2024 50 2 119 135 10.1590/s1677‑5538.ibju.2023.0578 38386784
    [Google Scholar]
  34. Dobrek L. Lower urinary tract disorders as adverse drug reactions: A literature review. Pharmaceuticals (Basel) 2023 16 7 1031 10.3390/ph16071031 37513941
    [Google Scholar]
  35. Petta S. Ciresi A. Bianco J. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 2017 12 11 e0186136 10.1371/journal.pone.0186136 29161258
    [Google Scholar]
  36. Di Stasi V. Maseroli E. Rastrelli G. SHBG as a marker of NAFLD and metabolic impairments in women referred for oligomenorrhea and/or hirsutism and in women with sexual dysfunction. Front. Endocrinol. (Lausanne) 2021 12 641446 10.3389/fendo.2021.641446 33854482
    [Google Scholar]
  37. Paschou S.A. Polyzos S.A. Anagnostis P. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020 67 1 1 8 10.1007/s12020‑019‑02085‑7 31538291
    [Google Scholar]
  38. Diamanti-Kandarakis E. Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev. 2012 33 6 981 1030 10.1210/er.2011‑1034 23065822
    [Google Scholar]
  39. Jones H. Sprung V.S. Pugh C.J.A. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2012 97 10 3709 3716 10.1210/jc.2012‑1382 22837189
    [Google Scholar]
  40. Lee J.Y. Shin D.W. Oh J.W. Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women. PLoS One 2017 12 8 e0182708 10.1371/journal.pone.0182708 28854246
    [Google Scholar]
  41. Pawlotsky J-M. Negro F. Aghemo A. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J. Hepatol. 2020 73 5 1170 1218 10.1016/j.jhep.2020.08.018 32956768
    [Google Scholar]
  42. Więdłocha M. Marcinowicz P. Sokalla D. Stańczykiewicz B. The neuropsychiatric aspect of the HCV infection. Adv. Clin. Exp. Med. 2017 26 1 167 175 10.17219/acem/37787 28397449
    [Google Scholar]
  43. Colaci M. Malatino L. Antonelli A. Fallahi P. Giuggioli D. Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev. Endocr. Metab. Disord. 2018 19 4 397 403 10.1007/s11154‑018‑9475‑y 30499080
    [Google Scholar]
  44. Hunter S.S. Gadallah A. Azawi M.K. Doss W. Erectile dysfunction in patients with chronic hepatitis C virus infection. Arab J. Gastroenterol. 2014 15 1 16 20 10.1016/j.ajg.2014.01.012 24630508
    [Google Scholar]
  45. Danoff A. Khan O. Wan D.W. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am. J. Gastroenterol. 2006 101 6 1235 1243 10.1111/j.1572‑0241.2006.00544.x 16771944
    [Google Scholar]
  46. Ferri C. Bertozzi M.A. Zignego A.L. Erectile dysfunction and hepatitis C virus infection. JAMA 2002 288 6 698 699 10.1001/jama.288.6.698 12169072
    [Google Scholar]
  47. Ma B.O. Shim S.G. Yang H.J. Association of erectile dysfunction with depression in patients with chronic viral hepatitis. World J. Gastroenterol. 2015 21 18 5641 5646 10.3748/wjg.v21.i18.5641 25987790
    [Google Scholar]
  48. Chung S.D. Keller J.J. Lin H.C. A case–control study of chronic prostatitis/chronic pelvic pain syndrome and colorectal cancer. BJU Int. 2012 110 4 550 554 10.1111/j.1464‑410X.2012.10929.x 22314042
    [Google Scholar]
  49. Triantos C.K. Tsintoni A. Karaivazoglou K. Male hepatitis C patients’ sexual functioning and its determinants. Eur. J. Gastroenterol. Hepatol. 2017 29 11 1241 1246 10.1097/MEG.0000000000000971 28914698
    [Google Scholar]
  50. Karaivazoglou K. Tsermpini E.E. Assimakopoulos K. Triantos C. Sexual functioning in patients with chronic hepatitis C: A systematic review. Eur. J. Gastroenterol. Hepatol. 2017 29 11 1197 1205 10.1097/MEG.0000000000000949 28834789
    [Google Scholar]
  51. Rao J. Danoff A. Bini E.J. Elevated sex hormone binding globulin levels may contribute to sexual dysfunction in men with chronic hepatitis C virus infection. J. Clin. Gastroenterol. 2009 43 1 94 95 10.1097/MCG.0b013e3180cabc14 18622303
    [Google Scholar]
  52. Abdelhamid A.A. Sherief M.H. Nemr N.A. Hassoba H.M. El-Sakka A.I. Homocysteine, insulin-like growth factor one and oestrogen levels in patients with erectile dysfunction-associated chronic hepatitis C virus infection. Andrologia 2018 50 10 e13116 10.1111/and.13116 30063074
    [Google Scholar]
  53. Retamozo S. Quartuccio L. Ramos-Casals M. Crioglobulinemia. Med. Clín. (Barc.) 2022 158 10 478 487 10.1016/j.medcli.2021.11.017 35216803
    [Google Scholar]
  54. Dove L.M. Rosen R.C. Ramcharran D. Wahed A.S. Belle S.H. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology 2009 137 3 873 10.1053/j.gastro.2009.05.060
    [Google Scholar]
  55. Masoud M.S. Ashfaq U.A. Khalid H. Interferon-free regimen for hepatitis C: Insight and management. Crit. Rev. Eukaryot. Gene Expr. 2018 28 4 373 384 10.1615/CritRevEukaryotGeneExpr.2018025121 30311586
    [Google Scholar]
  56. Akl E.M. Salah A.A. Effect of new oral direct acting antiviral therapy on sexual function in male patients with hepatitis C virus. Andrologia 2020 52 11 e13835 10.1111/and.13835 33070383
    [Google Scholar]
  57. Omar S.S. Ellakany W.I. Abdelmeniem I.M. Impact of sofosbuvir/] ledipasvir versus sofosbuvir/daclatasvir regimens on the male sexual function of patients with chronic hepatitis C. Infez. Med. 2021 29 3 456 463 10.53854/liim‑2903‑17 35146351
    [Google Scholar]
  58. Elshimi E. Morad W. Mohamad N.E. Male sexual dysfunction among egyptian patients with chronic hepatitis C virus infection before and after direct-acting antiviral drugs. J. Sex. Med. 2019 16 3 402 409 10.1016/j.jsxm.2019.01.309 30846113
    [Google Scholar]
  59. Alhefnawy M. Mohey A. Fathi A. Effect of direct-acting antiviral drugs on erectile functions among hepatitis C Patients: A prospective interventional study. Endocr. Metab. Immune Disord. Drug Targets 2022 22 3 310 317 10.2174/1871530321666210212143932 33583390
    [Google Scholar]
  60. El Kassas M. Salah E. Gad A. Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr. Med. Res. Opin. 2021 37 6 967 972 10.1080/03007995.2021.1901677 33688780
    [Google Scholar]
  61. Yu Y.F. Chen Y. Shen X.F. Wang R.J. Shen J.W. Fang Z.H. Entecavir improves the reproductive function of male patients with chronic hepatitis B. National J Androl 2020 26 4 326 330 33351299
    [Google Scholar]
  62. Liao X. Zhao S. Yin J. Sexual dysfunction in patients with chronic hepatitis B: Prevalence and risk factors. J. Sex. Med. 2022 19 2 207 215 10.1016/j.jsxm.2021.11.016 34969615
    [Google Scholar]
  63. Kim M. Kim S.Y. Rou W.S. Hwang S.W. Lee B.S. Erectile dysfunction in patients with liver disease related to chronic hepatitis B. Clin. Mol. Hepatol. 2015 21 4 352 357 10.3350/cmh.2015.21.4.352 26770923
    [Google Scholar]
  64. Meng X. Dai X. Huang J. The influence of male HBV infection on sperm quality, embryonic development, and assisted reproductive outcomes. Hum. Reprod. 2024 39 1 43 52 10.1093/humrep/dead235 37994690
    [Google Scholar]
  65. Üzel A. Ebik B. Bucaktepe G.E. Yolaçan R. Karabulut Ü. Uçmak F. Do oral antiviral drugs used in the treatment of chronic hepatitis B cause erectile dysfunction? Eur. J. Gastroenterol. Hepatol. 2024 36 2 184 189 10.1097/MEG.0000000000002672 37942730
    [Google Scholar]
  66. Singal A.K. Bataller R. Ahn J. Kamath P.S. Shah V.H. ACG clinical guideline: Alcoholic liver disease. Am. J. Gastroenterol. 2018 113 2 175 194 10.1038/ajg.2017.469 29336434
    [Google Scholar]
  67. Yan C. Hu W. Tu J. Li J. Liang Q. Han S. Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease. J. Transl. Med. 2023 21 1 300 10.1186/s12967‑023‑04166‑8 37143126
    [Google Scholar]
  68. Martínez-Riera A. Santolaria-Fernández F. González Reimers E. Alcoholic hypogonadism: Hormonal response to clomiphene. Alcohol 1995 12 6 581 587 10.1016/0741‑8329(95)02006‑3 8590623
    [Google Scholar]
  69. Acharya R.K. Panigrahi S. Samani M.J. Choudhary A.K. Prevalence and pattern of sexual dysfunction in male patients with alcohol dependence. Addict. Health 2022 14 3 192 197 10.34172/ahj.2022.1335 36544980
    [Google Scholar]
  70. Salari N. Hasheminezhad R. Almasi A. The risk of sexual dysfunction associated with alcohol consumption in women: A systematic review and meta-analysis. BMC Womens Health 2023 23 1 213 10.1186/s12905‑023‑02400‑5 37131197
    [Google Scholar]
  71. Karunakaran A. Prabhakaran A. Karunakaran V. Michael J.P. Erectile dysfunction in alcohol use disorder and the change in erectile function after one month of abstinence. J. Addict. Dis. 2024 42 2 112 121 10.1080/10550887.2022.2157199 36606722
    [Google Scholar]
  72. Karunakaran A. Michael J.P. The impact of abstinence from alcohol on erectile dysfunction: A prospective follow up in patients with alcohol use disorder. J. Sex. Med. 2022 19 4 581 589 10.1016/j.jsxm.2022.01.517 35236641
    [Google Scholar]
  73. Maimone S. Saffioti F. Oliva G. Erectile dysfunction in compensated liver cirrhosis. Dig. Liver Dis. 2019 51 6 843 849 10.1016/j.dld.2018.10.015 30467076
    [Google Scholar]
  74. Margreiter M. Heinisch B.B. Schwarzer R. Klatte T. Shariat S.F. Ferlitsch A. Lower urinary tract symptoms in patients with liver cirrhosis. World J. Urol. 2015 33 3 315 321 10.1007/s00345‑014‑1313‑6 24798455
    [Google Scholar]
  75. Paternostro R. Heinisch B.B. Reiberger T. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int. 2018 38 8 1427 1436 10.1111/liv.13704 29368385
    [Google Scholar]
  76. Huyghe E. Kamar N. Wagner F. Erectile dysfunction in end-stage liver disease men. J. Sex. Med. 2009 6 5 1395 1401 10.1111/j.1743‑6109.2008.01169.x 19207273
    [Google Scholar]
  77. Fakhry M. Mahfouz H. Abdelazeem K. Prevalence and risk factors of erectile dysfunction in cirrhotic patients: An observational study. Arab J. Urol. 2024 22 1 6 12 10.1080/2090598X.2023.2238933 38205383
    [Google Scholar]
  78. Jagdish R.K. Kamaal A. Shasthry S.M. Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: A randomized double blind placebo controlled trial. Hepatol. Int. 2023 17 2 434 451 10.1007/s12072‑021‑10264‑w 34775577
    [Google Scholar]
  79. Darmadi D. Pakpahan C. Ruslie R.H. Amanda B. Ibrahim R. The sex life of male patients with cirrhosis and its organic factors: What we have got so far? PLoS One 2023 18 2 e0280915 10.1371/journal.pone.0280915 36730272
    [Google Scholar]
  80. Gungor G. Perk H. Soyupek S. Baykal B. Demir M. Sezer M.T. Nebivolol protects erectile functions compared to Metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial. Eur. J. Intern. Med. 2022 103 69 75 10.1016/j.ejim.2022.06.013 35752527
    [Google Scholar]
  81. Chrysant S.G. Antihypertensive therapy causes erectile dysfunction. Curr. Opin. Cardiol. 2015 30 4 383 390 10.1097/HCO.0000000000000189 26049386
    [Google Scholar]
  82. Manolis A.A. Manolis T.A. Melita H. Manolis A.S. Eplerenone versus spironolactone in resistant hypertension: An efficacy and/or cost or just a men’s issue? Curr. Hypertens. Rep. 2019 21 3 22 10.1007/s11906‑019‑0924‑0 30826898
    [Google Scholar]
  83. Mitchell L. Govind V. Barela K. Goldstein A.T. Spironolactone may be a cause of hormonally associated vestibulodynia and female sexual arousal disorder. J. Sex. Med. 2019 16 9 1481 1483 10.1016/j.jsxm.2019.06.012 31351850
    [Google Scholar]
  84. Müller P.C. Kabacam G. Vibert E. Germani G. Petrowsky H. Current status of liver transplantation in Europe. Int. J. Surg. 2020 82S 22 29 10.1016/j.ijsu.2020.05.062 32454252
    [Google Scholar]
  85. Fidan C. Akdur A. Kirnap M. Analysis of quality of life, depression, and sexual function in patients on the liver transplant list. Turk. J. Gastroenterol. 2021 32 9 801 807 10.5152/tjg.2021.21229 34609310
    [Google Scholar]
  86. Park E.S. Villanueva C.A. Viers B.R. Siref A.B. Feloney M.P. Assessment of sexual dysfunction and sexually related personal distress in patients who have undergone orthotopic liver transplantation for end-stage liver disease. J. Sex. Med. 2011 8 8 2292 2298 10.1111/j.1743‑6109.2011.02264.x 21492399
    [Google Scholar]
  87. Magro J.T.J. Mendes K.D.S. Galvão C.M. Sexual aspects of liver transplant candidates and recipients: Evidence available in the literature. Rev. Lat. Am. Enfermagem 2018 26 0 e3033 10.1590/1518‑8345.2744.3033 30183871
    [Google Scholar]
  88. Chan M.Y. Chok K.S.H. Fung J.Y.Y. Ng S.L. Yiu M.K. Lo C.M. Prospective study on sexual dysfunction in male chinese liver transplant recipients. Am. J. Men Health 2019 13 2 1557988319835139 10.1177/1557988319835139 30836839
    [Google Scholar]
  89. Chiang H.C. Chien Y.C. Lin P.Y. Lee H.L. Chen Y.L. Assessing men with erectile dysfunction before and after living donor liver transplantation in real-world practice: Integrating laboratories into clinical settings. PLoS One 2018 13 11 e0206438 10.1371/journal.pone.0206438 30458009
    [Google Scholar]
  90. Nitsche R. Coelho J.C.U. Freitas A.C.T. Zeni Neto C. Martins E. Testosterone changes in patients with liver cirrhosis before and after orthotopic liver transplantation and its correlation with MELD. Arq. Gastroenterol. 2014 51 1 59 63 10.1590/S0004‑28032014000100012 24760066
    [Google Scholar]
  91. Gariani K. Toso C. Philippe J. Orci L.A. Effects of liver transplantation on endocrine function: A systematic review. Liver Int. 2016 36 10 1401 1411 10.1111/liv.13158 27163168
    [Google Scholar]
  92. Mei Y. Wang X. Li Y. Xu R. Feng X. Liver transplantation improves erectile function in patients with end-stage liver disease: A systematic review and meta-analysis. Transl. Androl. Urol. 2024 13 9 1795 1804 10.21037/tau‑24‑185 39434727
    [Google Scholar]
  93. Romano L. Pellegrino R. Sciorio C. Erectile and sexual dysfunction in male and female patients with celiac disease: A cross‐sectional observational study. Andrology 2022 10 5 910 918 10.1111/andr.13186 35419983
    [Google Scholar]
  94. Priadko K. Romano L. Olivieri S. Intestinal microbiota, intestinal permeability and the urogenital tract: is there a pathophysiological link? J. Physiol. Pharmacol. 2022 73 5 10.26402/Jpp.2022.5.01
    [Google Scholar]
  95. Romano L. Napolitano L. Crocetto F. Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms. Prostate 2024 84 6 513 524 10.1002/pros.24675 38353479
    [Google Scholar]
  96. Romano L. Pellegrino R. Arcaniolo D. Lower urinary tract symptoms in patients with inflammatory bowel diseases: A cross-sectional observational study. Dig. Liver Dis. 2023 56 4 628 634 10.1016/j.dld.2023.10.010
    [Google Scholar]
  97. Romano L. Fonticelli M. Miranda A. Sexual dysfunctions in inflammatory bowel disease: Role of Mediterranean diet and quality of life. Andrology 2024 Epub ahead of print10.1111/andr.13791 39492590
    [Google Scholar]
  98. Romano L. Zagari R.M. Arcaniolo D. Sexual dysfunction in gastroenterological patients: Do gastroenterologists care enough? A nationwide survey from the Italian Society of Gastroenterology (SIGE). Dig. Liver Dis. 2022 54 11 1494 1501 10.1016/j.dld.2022.05.016 35710521
    [Google Scholar]
  99. Dickstein D.R. Edwards C.R. Rowan C.R. Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus. Nat. Rev. Gastroenterol. Hepatol. 2024 21 6 377 405 10.1038/s41575‑024‑00932‑1 38763974
    [Google Scholar]
  100. Justice, equity, diversity and inclusion in gastroenterology and hepatology. Nat. Rev. Gastroenterol. Hepatol. 2024 21 10 661 10.1038/s41575‑024‑00985‑2 39327523
    [Google Scholar]
/content/journals/rrct/10.2174/0115748871355207250411202640
Loading
Sexual Dysfunctions in Chronic Liver Diseases: A Narrative Review on Prevalence and Putative Pathophysiologic Mechanisms
Bentham Science Publishers ; https://doi.org/10.2174/0115748871355207250411202640
/content/journals/rrct/10.2174/0115748871355207250411202640
/content/journals/rrct/10.2174/0115748871355207250411202640
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: erectile dysfunction ; Chronic liver diseases ; chronic viral hepatitis ; hypogonadism ; sexual dysfunctions ; liver cirrhosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test